Recently, the U.S. Food and Drug Administration (FDA) approved 18F-labeled flurpiridaz as another PET myocardial perfusion imaging (MPI) radiotracer for clinical use in adult patients with known or suspected coronary artery disease (CAD). This decision was based on recent results of a second phase 3
No takes yet. Share an insight, caveat, or question.
Schindler et al. (2025) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: